Billionaire Steve Cohen’s SAC Owns Nearly 8% of Zoetis Inc (ZTS)

Page 1 of 2

SAC Capital Advisors, the hedge fund managed by billionaire Steve Cohen and his team, has filed a 13G with the SEC to report that it owns 7.6 million shares of Zoetis Inc (NYSE:ZTS), an animal pharmaceuticals company which was spun out from Pfizer in February (the stock is about flat from its levels in early February). According to the filing, this gives the fund control of 7.7% of the total outstanding shares. We track quarterly 13F filings from hundreds of hedge funds, including SAC, as part of our work researching investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year). We can see from our database that Cohen had owned about 730,000 shares as of the end of March (find SAC’s favorite stocks), so most of the fund’s purchases have come in the last few months rather than immediately after the spinout.

Zoetis Inc (NYSE:ZTS) has released a 10-Q for the first quarter of 2013, though investors should of course be aware that as a recent spinout the company is in a period of transition and that any comparison to a year ago will not be completely perfect. In any case, the report shows Zoetis Inc (NYSE:ZTS)’s revenue grew by 4% during the quarter compared to Q1 2012, and earnings were up even if we add back higher restructuring charges in the prior year period. The 10-Q showed net income of $140 million for the quarter- 28 cents per share- and about $280 million in cash flow from operations, with little capital expenditures required.

Steven CohenIf we annualize last quarter’s earnings per share figure we get a P/E multiple of 28. Wall Street analysts are expecting $1.62 in EPS for 2014, which would require improvements on the bottom line. We’d note that many hedge funds and value investors like to invest in spinouts on the theory that management of the new company is better able to focus on operations without having to concern themselves with the needs and initiatives of the parent company. Read more about investing in spinouts. However, many market players are bearish as shown by the fact that 19% of the float is held short.

VCA Antech Inc (NASDAQ:WOOF) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) are two other animal health companies, though they tend to focus more on pets and on laboratory and hospital services (as opposed to pharmaceutical products) than Zoetis Inc (NYSE:ZTS) does. VCA Antech carries a high trailing earnings multiple, but the sell-side expects the company to improve over the next year and a half and so the forward P/E comes in at only 15.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!